Introduction
Streptococcus pneumoniae (pneumococcus) is responsible for episodes of acute otitis media (AOM), pneumonia, bacteraemia and meningitis, mainly in children, the elderly and the immunocompromised, and may be directly responsible for as many child deaths as HIV/AIDS, malaria and tuberculosis combined (O'Brien et al., 2009) . The 23-valent pneumococcal polysaccharide vaccine (PPSV23), introduced in 1983, is recommended for all adults aged 65 years and older or adults younger than age 65 years with chronic lung disease, chronic cardiovascular diseases, cirrhosis, diabetes mellitus, functional or anatomic asplenia, etc., as well as for children over 2 years of age who were at a substantially increased risk of developing pneumococcal infection (Centers for Disease
Control and Prevention (CDC), 2013). A 7-valent conjugate vaccine (PCV7) was recommended for universal use in children aged 23 months and younger in the United
States in 2000 (American Academy of Pediatrics  Committee on Infectious Diseases, 2000) . In the following years its use began in Europe (2001) and other parts of the world. PCV7 contains conjugate capsular polysaccharide directed at 7 (4, 6B, 9V, 14, 18C, 19F and 23F) . Since 2000, the widespread use of PCV7 for children has reduced the incidence of pneumococcal disease in all age groups (Whitney et al., 2003) . A few years after its introduction, the rates of AOM and invasive pneumococcal disease (IPD) caused by PCV7 serotypes in children under 5 decreased dramatically (Nuorti et al., 2010) .
It is now clear, however, that the pneumococcal population has changed since the widespread introduction of PCV7. Non-PCV7 serotype isolates have increased among asymptomatic carriers in a process known as "serotype replacement" and have become increasingly responsible for cases of IPD (Weinberger et al., 2011) . Although some PCV7 serotypes appear to offer cross-protection against certain non-PCV7 serotypes, e.g., 6B offers protection against 6A, this has not been clearly demonstrated for 19F and 19A (Hausdorff et al., 2010) . Indeed, the incidence of infections caused by multiresistant 19A pneumococci has increased since PCV7 vaccination became 4 common (Liñares et al., 2010; Richter et al., 2013) . In the pre-PCV7 era, 19F and 19A were among the most common serotypes involved in AOM worldwide (Rodgers et al., 2009 ). Nowadays, multiresistant S. pneumoniae 19A isolates remain the most commonly encountered in many countries, while the number of 19F infections has greatly diminished (Hanage et al., 2011; Spijkerman et al., 2011) . Evidence that serotype 19A is well capable of colonizing the nasopharynx and causing AOM has recently been reported using a chinchilla otitis media model (Laufer et al., 2010) . The explanation for the notable colonizing capacity of serotypes 19F and 19A remains unclear, although a direct relationship between the success of a serotype during nasopharyngeal carriage and its capsular polysaccharide (CPS) biochemistry has been suggested (Weinberger et al., 2009) . It has also been reported that CPS biosynthesis interferes with pneumococcal growth in a nutritionally limited environment (as the nasopharynx is thought to be), probably by competition for energy with the organism's central metabolism. This suggests that the serotype-specific nasopharyngeal carriage prevalence in vivo is predicted by the growth phenotype (Hathaway et al., 2012) .
The vast majority of infections are now thought to be caused by microorganisms growing as part of a biofilm (Wolcott and Ehrlich, 2008) . A biofilm is a thin layer of microorganisms embedded in an extracellular matrix that adheres to the surface of an organic or inorganic structure. Recent reports have documented the in vivo formation of S. pneumoniae biofilms on adenoid and mucosal epithelial tissues in children with recurrent or chronic ear infections (for a recent review, see (Domenech et al., 2012) . A number of laboratories have also shown that both the in vivo and in vitro formation of pneumococcal biofilms is hindered by the presence of CPS, i.e., the presence of a capsule inhibits pneumococcal biofilm development (Domenech et al., 2012) . Indeed, encapsulated clinical pneumococcal isolates and isogenic transformants form significantly less biofilm than non-encapsulated strains , and an inverse relationship is reported between the ability of non-encapsulated variants to form biofilms and the amount of CPS they produce (Domenech et al., 2009) . These results agree with the proposal that pneumococci regulate CPS expression in their transition 5 from nasopharyngeal carriage associated with biofilm development to IPD (Hammerschmidt et al., 2005) .
In contrast to that previously thought, this paper reports that clinical isolates of serotypes 19F and 19A (but not 19B or 19C) , as well as isogenic transformants expressing the CPS of 19F or 19A, are good biofilm producers. This may explain the prevalence of these serotypes in the human nasopharynx. Studies with other serogroups suggest that the presence of a specific disaccharide in the CPS may be important for promoting biofilm formation. (Fig. 1) , and the immunochemical similarities of all four inferred from cross-reactivity with factor typing sera (Beynon et al., 1992) . As expected, the complexity of their chemical structures is reflected in that of the corresponding capsular gene clusters (Beynon et al., 1992) . The immunological cross-reactions revealed by the capsular reaction showed that serotypes 7B, 7C, 19B, 19C, 24F, 24B and 40 have a common antigenic determinant known as 7h (Henrichsen, 1995) . Comparisons with the primary structures of serotypes 19B and 19C agree with a previous proposal (Beynon et al., 1992) that the 7h antigen corresponds to the disaccharide element (Fig. 1) . Given the reported inhibitory effect of CPS on biofilm formation, the biofilm-forming behavior of the 19F and 19A clinical isolates was unexpected. However, S. pneumoniae isolates show wide genetic variability beyond that of CPS formation (Croucher et al., 2011) , and the genetic background of an isolate may strongly influence its capacity to form a biofilm (Domenech et al., 2012) . To reduce the influence of genetic variability, isogenic capsular transformants producing serogroup 19 capsules were constructed using the nonencapsulated M11 strain as a recipient (Table 1 ). The biofilm-forming capacity of the corresponding transformants almost paralleled those of the corresponding parental clinical isolates (Fig. 2) . Notably, strain P192 formed much more biofilm than its parent G54, confirming the importance of genetic background in biofilm development.
Results

Biofilm
The distinctive biofilm-forming behavior of the 19F isolates was further examined by construction of strain P194, a binary encapsulated transformant of strain P192 that simultaneously expressed the CPS of serotypes 19F and 37. Pneumococci expressing serotype 37 CPS are virtually unable to form biofilms , so it was expected that the transformant would show a drastic reduction in biofilm-forming capacity compared to the encapsulated P192 parental strain (Fig. 2) .
Together, the above results indicate that, in addition to genetic background, the chemical composition/structure of the CPS is crucial to biofilm-forming capacity. A close comparison of the primary structures of the repeating units of the CPS of serotypes 19F and 19A on one hand, and 19B and 19C on the other, suggest that the (present in serotype 19F and 19A CPSs respectively, but not in 19B and 19C capsules) may be important for promoting biofilm formation.
Biofilm-forming capacity of other pneumococcal CPSs with disaccharides similar to -
D-Glcp-(1→3)--L-Rhap
The disaccharide -D-Glcp-(1→3)--L-Rhap-(1→ is present in the CPS of the four known serotypes of serogroup 6 (Fig. 3A) . Moreover, the CPSs of all four are characterized by the presence of a rhamnose-ribitol linkage. However, the CPSs of 6B and 6D have a 1→4 rhamnose-ribitol linkage, whereas those of 6A and 6C have a 1→3 rhamnose-ribitol linkage; 6A and 6B CPSs also contain galactose, while those of 6C and 6D do not (Bratcher et al., 2010) .
We previously reported ) that a serotype 6B clinical isolate and an M11 transformant expressing the 6B capsule showed some 70% of the biofilmforming capacity of the unencapsulated M11 strain. The analysis of other members of this serogroup, namely serotypes 6A and 6C (no serotype 6D isolate was available)
showed that both clinical isolates and isogenic transformants expressing these capsules formed ≥40% of the quantity of biofilm formed by the nonencapsulated control strain (Fig. 3B) . These results agree with the hypothesis that the presence of -D-Glcp-(1→3)--L-Rhap-(1→ in the CPS is strongly related to biofilm-forming capacity. Dob1 has long been recognised as a hybridoma-secreted human immunoglobulin G2
antibody that binds to and opsonizes pneumococci of serogroup 6 (Sun et al., 1999) . It can bind to synthetic capsular carbohydrates
is present in the CPS of serotypes 6A, 6B, 6C, 6D and 19A, but not in that of 19F. Purified Dob1 was added to strain P181 (a serotype 19A transformant) in a standard biofilm-forming assay. When Dob1 was used in amounts that did not cause growth inhibition, no changes in biofilm formation were seen (data not shown).
The biofilm-forming capacity of serotypes 18A, 18B and 18C was also investigated. (Fig. 4A ). In addition, serotype 18C has a glycerol-phosphate substituent required for the antigenicity of the 18C CPS to be conserved (Chang et al., 2012) . Among all the members investigated of this serogroup, only one clinical isolate of serotype 18C was able to form a substantial amount of biofilm, but the corresponding M11 transformant (strain P202) showed no significant biofilm-forming capacity (Fig. 4B) .
Discussion
The antiphagocytic properties of S. pneumoniae CPS are essential for it to show systemic virulence (Hyams et al., 2010) . At least 95 different pneumococcal serotypes are known, each with a biochemically distinct CPS. The most recent descriptions include serotypes 6E (Ko et al., 2013) , 6F and 6G (Oliver et al., 2013a) .
It is likely that additional serotypes remain to be described (note that serological heterogeneity among serotype 20 isolates has recently been reported (Burton and Nahm, 2012)). There is also growing evidence that pneumococci can change their CPS structure and, consequently, their immunological properties through minimal genetic modifications (Oliver et al., 2013b; Oliver et al., 2013a) . The distribution of serotypes worldwide is also continuously evolving since it depends on the year, country, age of the individual and site of isolation, and use of antibiotics. The widespread use of PCV7 for the immunization of children has strongly modified the prevalence of S. pneumoniae serotypes; those covered by PCV7 have declined while nonvaccine serotypes have become more common. In particular, the noticeable proliferation of multiresistant 19A pneumococci has been associated with PCV7 use (Hulten et al., 2013) , although increases had been reported before the introduction of the vaccine ), perhaps as a result of antibiotic pressure (Hulten et al., 2013) . The two serotypes that show the strongest colonization capacity, 19A and 6C (Laufer et al., 2010) , are not covered by the PCV7 vaccine. Following the introduction of PCV7, serotype 19A has emerged as one of the most commonly encountered clinical serotypes (Hulten et al., 2013) . It has been suggested that any effect of PCV7 on 19A would be limited to disease prevention once colonization has occurred, rather than any prevention of colonization itself (Hausdorff et al., 2010) . The discovery of the strong colonization capacity of serotypes 19A and 6C should therefore be taken into account in the design of new pneumococcal conjugated vaccines.
A 13-valent pneumococcal conjugate vaccine (PCV13) has recently been licensed for use in children and adults at risk or with immunocompromising conditions (Advisory Committee on Immunization Practices, 2012). PCV13 is identical in formulation to PCV7 but with six additional targets covered (1, 3, 5, 6A, 7F, and 19A). As observed for PCV7, the widespread use of PCV13 will likely produce a decline in IPD caused by the serotypes covered, as well as that inflicted by certain related serotypes, e.g., serotype 6C (McEllistrem and Nahm, 2012) . In fact, a recent study carried out in 8 children hospitals in the United States has shown that IPD decreased 42% overall and 53% for children <24 months of age in 2011 compared with the 3 years before PCV13 use . Unfortunately, it remains unknown whether this vaccine can protect against infection by serotype 6D; the recent emergence of multidrug-resistant 6D pneumococci is a cause of much concern (Ko et al., 2012) . Other non-PCV13 serotypes that appear to be rapidly increasing in prevalence include 24F (Ardanuy et al., 2012) , 35B (Richter et al., 2013) , 33F, 22F, 12, 15B, 15C, 23A and 11 . As shown in the present work, serotype 24F isolates do not usually form biofilms in vitro. The ability of serotypes 35B, 33F, 22F, 12, 15B, 15C, 23A and 11 pneumococci to produce biofilms was not investigated. The huge variety of pneumococcal serotypes that exist warrants studies on non-PCV13 emerging serotypes, which should be carefully monitored. The capacity to form biofilms, which the present work shows can be rapidly tested in vitro, could help in predicting the expansion of post-PCV13 pneumococcal isolates.
Experimental procedures
Strains, plasmids, media and genetic transformation
The pneumococcal strains of the different serotypes used in this study are listed in Table   1 . All strains were grown in C medium (Lacks and Hotchkiss, 1960) supplemented (C+Y medium), or not, with 0.08% yeast extract. The plasmid pDLP49, which encodes the Tts -glucosyltransferase of S. pneumoniae responsible for the synthesis of type 37 CPS, has been previously described (Llull et al., 1999; Llull et al., 2001) . S. pneumoniae was transformed with chromosomal or plasmid DNA by treating precompetent cells with 100 ng/mL of synthetic competence-stimulating pheromone 1 at 37°C for 10 min to induce competence, followed by incubation at 30°C during DNA uptake. Encapsulated transformants of strain M11 were enriched by successive transfers of the transformed culture to C medium containing 0.08% bovine serum albumin, and supplemented with 0.5 L/mL of anti-R antiserum before plating (Mollerach et al., 1998) . Anti-R (antisomatic) antiserum contains group-specific agglutinins, which, at the proper dilution, agglutinate only unencapsulated pneumococci. Serotyping by the capsular reaction (Quellung) was kindly performed by L. Vicioso (Spanish Pneumococcal Reference Laboratory, Majadahonda, Spain).
Biofilm formation assay and quantification
The optimal conditions for biofilm formation by pneumococcal cells have been previously described . In short, all biofilms were formed in Costar 3595 96-well PST microtiter plates (Corning). Cells were grown in CpH8 medium to an optical density at 550 nm (OD 550 ) of 0.5-0.6, sedimented by centrifugation, resuspended in an equal volume of CpH8 medium, and diluted 1/10.
Two hundred microliter aliquots were dispensed into each well. After 6 h of incubation at 34°C, the biofilm formed was stained with 0.2% crystal violet and rinsed three times with distilled water to remove nonadherent bacteria. After solubilizing the biofilm in 95% ethanol (200 μl per well), the OD 595 was determined using an Anthos 2020 microplate absorbance reader (Anthos Labtec Instruments).The human antibody Dob1 was diluted 1/10 to 1/40 and used to test for the inhibition of biofilm formation was kindly provided by M. H. Nahm (University of Alabama at Birmingham, AL, USA).
Multilocus Sequence Typing
Multilocus sequence typing (MLST) was performed as described elsewhere (Enright and Spratt, 1998) 
